The economic aspects of hepatitis C-- implications for haemophilia.
This paper considers the literature relating to the course of hepatitis C infection and its implications for those with haemophilia. It goes on to discuss a model that assessed the economic aspects of treating hepatitis C cases with interferon-alpha, discusses recent changes in recommended treatment of hepatitis C and critically reviews the model and its application to patients with haemophilia.
Roberts
J A
JA
Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. j.roberts@LSHTM.ac.uk
D000328:Adult; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005355:Fibrosis / Q000209:etiology; D017048:Health Care Costs; D006467:Hemophilia A / Q000191:economics* / Q000821:virology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008954:Models, Biological; D011788:Quality of Life; D011994:Recombinant Proteins; D015996:Survival Rate
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins